Obicetrapib monotherapy significantly improved the lipid profile of patients with heterozygous familial hypercholesterolemia ...

A designer has created a concept car capable of driving on both water and land. Imagined by Bernardo Pereira, a student at ...

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

Many cruise passengers don't consider themselves gamblers, yet they often take risks with their cabin choices. In this video, ...

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

COPD cases are rising in women. Uncover the latest insights to enhance diagnosis and treatment in your women patients.

The addition of statin medications to contemporary therapies like ibrutinib could significantly improve survival for patients ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) after 36 ...

The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...